Neue Thrombozytenaggregationshemmer in der Therapie der instabilen Angina

Abstract

Unstable angina is a critical phase of coronary heart disease with a risk for myocardial infarction or death of up to 20% within 30 days. Glycoprotein IIb/IIIa antagonists are a new class of potent antiplatelet drugs. In several large randomized trials, it has been well established that the antibody abciximab, and the low molecular synthetic compounds tirofiban and eptifibatide, reduce the cardiac event rate by 10 to 70% in patients with and without percutaneous interventions. This effect was found to be predominately present in patients with elevated troponins. Accordingly, glycoprotein IIb/IIIa antagonists represent a major achievement for the treatment regimen of patients with unstable angina.

Recombinant Factor VIIa Reduces Bleeding Risk in Patients on Platelet Aggregation Inhibitors Immediately prior to Renal Transplantation – A Retrospective Analysis

“…Moreover, the possible over-the-counter (OTC) purchase of ASA for pain treatment leads to uncontrolled use. More recent drugs such as glycoproteinIIb/IIIa receptor antagonists, ADP receptor antagonists or thromboxane receptor antagonists seem to be more effective in the secondary prophylaxis of a thrombotic event and in the prevention of re-stenoses after vascular interventions as well as implantation of coronary stents, but are associated with an increased risk of bleeding [1,2] . The inhibition of platelet function desired to date may Key Words rFVIIa ؒ Kidney transplantation ؒ Platelet aggregation inhibitors Abstract Background: Transplant surgery often requires an effective preoperative treatment which allows to reduce the risk of bleeding caused by platelet aggregation inhibitors without major delay.…”